Magnetic Nanoparticle Drug Delivery Across Blood-Brain Barrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HIV-associated neurocognitive disorder (HAND) are inadequate due to the inability of drugs to cross the blood-brain barrier and a lack of understanding of the underlying molecular mechanisms, particularly in patients who also abuse cocaine, leading to increased severity and incidence of HAND.
Innovation Solution
A novel therapeutic approach using bi-functional plant molecule Withaferin-A (WA) conjugated with magnetic nanoparticles (MENPs) and microRNA 107, along with a cocaine antagonist, to deliver therapeutic cargo across the blood-brain barrier, targeting HIV infection and amyloid beta protein eradication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs are administered to treat HAND, then HIV infection can be suppressed, but the drugs cannot cross the blood-brain barrier to reach the brain effectively
Solution Approach 1:
The patent uses magnetic nanoparticles as an intermediary carrier to transport therapeutic agents across the blood-brain barrier. The nanoparticles are magnetically guided to the brain and release their cargo in response to alternating current stimulation, solving the delivery problem without compromising treatment efficacy
Solution Approach 2:
The patent changes the physical state and delivery parameters of therapeutic agents by conjugating them to magnetic nanoparticles. This allows the drugs to be transported through the bloodstream, magnetically directed to the brain, and released under controlled conditions, overcoming the blood-brain barrier limitation
2Adaptability or versatility
If multiple therapeutic agents are combined to address both HIV and amyloid beta, then comprehensive treatment coverage is achieved, but the formulation complexity increases
Solution Approach 1:
The patent merges multiple therapeutic agents (HIV inhibitors, BACE-1 inhibitors, and cocaine antagonists) into a single nanoparticle formulation. This unified approach delivers all necessary treatments simultaneously to the brain, achieving comprehensive coverage while managing complexity through a single integrated system
Solution Approach 2:
The magnetic nanoparticle platform serves multiple functions: it acts as a carrier for diverse therapeutic agents, provides magnetic guidance to the brain, enables controlled release through alternating current, and can target multiple pathological processes (HIV infection, amyloid beta production, and cocaine effects) with a single system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively reduces HIV infection, inhibits amyloidogenesis, and improves cognitive functions in HIV-infected cocaine addicts by selectively targeting and releasing therapeutic agents within the brain, addressing both HIV and cocaine-induced neuropathological hallmarks of HAND.
Implementation Method 1
applying to the subject magnetic forces to guide the MENPs across the BBB and into brain parenchyma
Implementation Method 2
The therapeutic cargo is released into the brain parenchyma by applying to the subject an alternating current
Data Source
AI summary
The invention pertains to a formulation comprising magnetic nanoparticles (MENPs) conjugated to or mixed with a therapeutic cargo, the therapeutic cargo comprising an HIV inhibitor, an inhibitor of BACE-1 activity or expression, and a cocaine antagonist. In one embodiment, the formulation comprises WA, miR-107, and BD1063. The MENPs conjugated or mixed with the therapeutic cargo can be encapsulated within liposomes. The liposomes can be surface modified with an affinity ligand that targets the liposomes to the brain. The invention also pertains to a method of treating an HIV infection in a subject having cocaine addiction, by administering to the subject the formulation of the invention and applying to the subject magnetic forces to guide the MENPs across the blood brain barrier and into brain parenchyma and releasing the therapeutic cargo into the brain parenchyma by applying to the subject an alternating current.